Determination of mRNA, and protein levels of p53, MDM2 and protein kinase CK2 subunits in F9 cells after treatment with the apoptosis-inducing drugs cisplatin and carboplatin

International Journal of Biochemistry and Cell Biology

Volumn 31, Issue 6, 1999, Pages 661-670

  Siemer, S ^a   Ornskov D ^b   Guerra, B ^b   Boldyreff, B ^b   Issinger, O G ^b  

^a Klin Poliklin Urologie K   (Germany)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Carboplatin; Cisplatin; MDM2; p53; Protein kinase CK2

Indexed keywords

CARBOPLATIN; CASEIN KINASE II; CISPLATIN; COMPLEMENTARY DNA; MESSENGER RNA; PROTEIN KINASE; PROTEIN MDM2; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; ENZYME SUBUNIT; IMMUNOBLOTTING; MOUSE; NONHUMAN; NORTHERN BLOTTING; POLYACRYLAMIDE GEL ELECTROPHORESIS; TERATOCARCINOMA; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARBOPLATIN; CASEIN KINASE II; CISPLATIN; IN SITU NICK-END LABELING; MICE; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RNA, MESSENGER; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

MURINAE;

EID: 0033058722     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1357-2725(99)00020-5     Document Type: Article

References (32)

1. Issinger O-G. Casein kinases: pleiotropic mediators of cellular regulation. Pharmac. Ther. 59:1993;1-30.
2. Allende J.E., Allende C.C. Protein kinases. 4. Protein kinases CK2: an enzyme with multiple substrates and a puzzling regulation. FASEB. 9:1995;313-323.
3. Pinna L.A., Meggio F. Protein kinase CK2 ('casein kinase-2') and its implication in cell division and proliferation. Prog. Cell. Cycle. Res. 3:1997;77-97.
4. Münstermann U., Fritz G., Seitz G., Lu Y., Schneider H.R., Issinger O-G. CK II is elevated in solid tumours and rapidly proliferating non-neoplastic tissue. Eur. J. Biochem. 189:1990;251-257.
5. Guerra B., Niefind K., Pinna L.A., Schomburg D., Issinger O-G. Expression, purification and crystallisation of the catalytic subunit of protein kinase CK2 from zea mays. Acta Crystallogr. D. Biol. Crystallogr. 54:1998;143-145.
6. Niefind K., Guerra B., Pinna L.A., Issinger O-G., Schomburg D. Crystal structure of the catalytic subunit of protein kinase CK2 from Zea mays at 2.1 A resolution. EMBO J. 17:1998;2451-2462.
7. Guerra B., Issinger O.-G. Protein kinase CK2 and its role in cellular proliferation and pathology. Electrophoresis. 20:1999;391-408.
8. Herrmann C.P., Kraiss S., Montenarh M. Association of casein kinase II with immunopurified p53. Oncogene. 6:1991;877-884.
9. Chen M., Li D., Krebs E.G., Cooper J.A. The casein kinase II beta subunit binds to Mos and inhibits Mos activity. Mol. Cell. Biol. 17:1997;1904-1912.
10. Guerra B., Issinger O-G. p53 and the ribosomal protein L5 participate in high molecular mass complex formation with protein kinase CK2 in murine teratocarcinoma cell line F9 after serum stimulation and cisplatin treatment. FEBS Lett. 434:1998;115-120.
11. Boldyreff B., Issinger O-G. A-Raf kinase is a new interacting partner of protein kinase CK2 beta subunit. FEBS Lett. 403:1997;197-199.
12. Hagemann C., Kalmes A., Wixler V., Wixler L., Schuster T., Rapp U.R. The regulatory subunit of protein kinase CK2 is a specific A-Raf activator. FEBS Lett. 403:1997;200-202.
13. Chu G. Cellular responses to cisplatin. J. Biol. Chem. 269:1994;787-790.
14. O'Connor P.M., Jackman J., Bae I., Myers T.G., Fan S., Mutoh M., Scudiero D.A., Monks A., Sausville E.A., Weinstein J.N., Friend S., Fornace A.J. Jr., Kohn K.W. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 57:1997;4285-4300.
15. Shelling A.N. Role of p53 in drug resistance in ovarian cancer. Lancet. 349:1997;744-745.
16. Wu G.S., El-Deiry W.S. Apoptotic death of tumor cells correlates with chemosensitivity, independent of p53 or Bcl-2. Clin. Cancer Res. 2:1996;623-633.
17. Ko L.J., Prives C. Puzzle and paradigm. Genes Develop. 10:1996;1054-1072.
18. Barry M.A., Behnke C.A., Eastman A. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem. Pharmacol. 40:1990;2353-2362.
19. Sorenson C.M., Barry M.A., Eastman A. Analysis of events associated with cell cycle arrest at G2 and cell death induced by cisplatin. J. Natl. Cancer Inst. 82:1990;745-749.
20. Ormerod M.G., Orr R.M., Peacock J.H. The role of apoptosis in cell killing by cisplatin: a flow cytmetric study. Br. J. Cancer. 69:1994;93-100.
21. Gill I., Muggia F.M., Terhegen P.M., Michael C., Parker J.R., Kortes V., Grunberg S., Christian M.C., Reed E., den Engelse L. Dose-escalation study of carboplatin (day 1) and cisplatin (day3): tolerance and relation to leukocyte and buccal cell platinum-DNA adducts. Ann. Oncol. 2:1991;115-121.
22. Reedijk J. The relevance of hydrogen bonding in the mechanism of action of platinum antitumor compounds. Inorg. Chim. Acta. 198:1992;873-881.
23. Blommaert F.A., van Dijk-Knijnenburg H.C.M., Dijt F.J., den Engelse L., Baan E.A., Berends F., Fichtinger-Schepman A.M.J. Formation of DNA Adducts by the anticancer drug carboplatin: different nucletide sequence preferences in vitro and in cells. Biochemistry. 34:1995;8474-8480.
24. Stevens L., Little C. Spontaneous testicular teratomas in an inbred strain of mice. Proc. Natl. Acad. Sci. USA. 40:1994;1080-1087.
25. Walt H., Oosterhuis J., Stevens C. Experimental testicular germ cell tumorigenesis in mouse strains with and without spontaneous tumors differs from development of germ cell tumors of the adult human testis. Int. J. Androl. 16:1993;267-271.
26. Langley R., Palayoor S., Coleman C., Bump E. Radiation-induced apoptosis in F9 teratocarcinoma cells. Int. J. Radiat. Biol. 65:1994;605-610.
27. Riou G., Barrois M., Prost S., Terrier M.J., Theodore C., Levine A.J. The p53 and mdm-2 genes in human testicular germ-cell tumors. Mol. Carcinog. 12:1995;124-131.
28. Zamble D.B., Jacks T., Lippard S.J. p53-dependent and -independent responses to cisplatin in mouse testicular teratocarcinoma cells. Proc. Natl. Acad. Sci. USA. 95:1998;6163-6168.
29. Mosner J., Mummenbrauer T., Bauer C., Sczakiel G., Grosse F., Deppert W. Negative feedback regulation of wildtype p53 biosynthesis. EMBO J. 14:1995;4442-4449.
30. Ewen M.E., Miller S.J. p53 and translational control. Biochim. Biophys. Acta. 1242:1996;181-184.
31. Weller M. Predicting response to cancer chemotherapy: the role of p53. Cell Tissue Res. 292:1998;435-445.
32. Lutzker S.G., Levine A.J. A functionally inactive p53 protein in teratocarcinoma cells is activated by either DNA damage or cellular differentiation. Nat. Med. 2:1996;804-810.